Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AMT, beneficiary, calendar, consecutive, delisted, delisting, disagreement, donut, effectuated, enhanced, excise, grace, hole, improbable, inflationary, IRA, magnitude, Marwan, nil, outpace, PCT, premium, regain, Sabbagh, tendered
Removed:
analyzed, asymptomatic, bank, baseline, beneficial, biological, depth, detectable, diarrhea, DNA, embedded, endpoint, gastrointestinal, implicit, LifeSci, maximize, NaN, nausea, ordinary, passing, pocket, precautionary, prepayment, preserve, presidential, preventive, recovered, remained, saliva, settled, sister, subgroup, supplied, survival, virtually
Filing tables
Filing exhibits
QNCX similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)
In connection with the Quarterly Report of Quince Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 9, 2022 |
| By: | /s/ Dirk Thye |
|
|
| Dirk Thye |
|
|
| President and Chief Executive Officer |
|
|
| (Principal Executive Officer) |